« Return to News | R&D Trends | Drug Sponsors

Nodality, Pfizer form multi-year collaboration on autoimmune disease

Thursday, August 9, 2012 02:16 PM

Nodality, a San Francisco-based personalized medicine biotech, has formed a strategic collaboration to provide proprietary single cell network profiling (SCNP) technology as a tool for the development of Pfizer compounds.

The agreement establishes a multi-year, collaborative effort that will initially focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis and drug profiling. The agreement also provides Pfizer the option to engage Nodality in companion diagnostics development. The terms of the agreement include an upfront payment, R&D funding and success-based milestone payments.

"This collaboration, which is Nodality's second major strategic pharma partnership this year, provides continuing validation of the value the SCNP platform technology can bring to drug development,” said Michael Goldberg, executive chairman and interim CEO, Nodality.

"Our partnership with Nodality exemplifies Pfizer's commitment to precision medicine by providing us with earlier insight into a compound's potential clinical profile, which can help reduce attrition rates, accelerate development and improve patient targeting,” said Jose-Carlos Gutierrez-Ramos, senior vice president of biotherapeutics R&D, Pfizer.

Pfizer Venture Investments has been an investor in Nodality since 2008.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.